Mechanism

How it works

Cardiogen functions as a peptide bioregulator by penetrating cell nuclei and interacting directly with chromatin, modulating gene expression in cardiomyocytes to upregulate proteins associated with cellular repair, anti-apoptotic signaling, and extracellular matrix maintenance. It is believed to activate transcription factors that govern cardiomyocyte survival pathways, potentially via NF-κB modulation and upregulation of cardioprotective proteins such as heat shock proteins. By normalizing protein synthesis in cardiac cells, it may slow or partially reverse age-related functional decline in the myocardium.

Reported in research

Benefits

May support cardiomyocyte survival and reduce apoptosis in cardiac tissue
Potentially reduces cardiac fibrosis and preserves myocardial contractility
May contribute to improved cardiac biomarkers in elderly or compromised patients (limited human data)
Shows cytoprotective properties in preclinical models of ischemia and oxidative stress

Context, not a prescription

Dosing

Typical range: 10–20 mcg/day (research dosing); 20 mg vials used in extended protocols (Subcutaneous, Intramuscular)
Cycle length: 10–30 days, repeated 2–3 times per year
Half-life: ~Unknown; estimated short (<2 hours) based on peptide class

Safety

Side effects & contraindications

Possible side effects

Injection site reactions (mild redness or discomfort)
Transient fatigue reported anecdotally
Potential mild hypotension at higher doses (theoretical)

Contraindications

Known hypersensitivity to any component of the formulation
Active cardiac arrhythmias without medical supervision
Pregnancy and breastfeeding (insufficient safety data)

Research information, not medical advice. Always consult a licensed clinician before considering any peptide.

In depth

Full profile

What it does

Potential improvements in cardiac-related markers, reduced fatigue linked to poor cardiac output, and general sense of cardiovascular ease — though these are subtle and not universally reported.

How it works

Imagine your heart cells are like employees who've been working a very long shift — they're tired and making mistakes. Cardiogen is like a manager who walks in, looks at the instruction manual (your DNA), and highlights the right sections so the employees remember how to do their jobs properly again.

After injection, the peptide is absorbed and reaches cardiac tissue, where it interacts with the genetic machinery inside heart muscle cells to encourage healthy protein production and cell maintenance. It does not dramatically stimulate the heart like caffeine or a drug — it works subtly at the cellular level.

What to expect

Effects are gradual; most users in research protocols noted changes over 2–4 weeks of consistent use.

Week 1: Body adjusts to the peptide; minimal noticeable changes; injection site reactions may occur
Weeks 2-4: Cellular repair processes begin; some users report slightly improved endurance or reduced chest tightness (anecdotal)
Weeks 4-8: Continued cytoprotective activity; markers of cardiac stress may begin to normalize in research settings; effects plateau and cycle typically ends

Good to know

Start with the lower end of the dosing range and assess tolerance
Always use sterile technique for injections to avoid infection

Staying safe

Mild soreness or redness at the injection site
Occasional tiredness in the first few days

Avoid if you have:

Anyone with serious heart conditions who is not under medical supervision
Pregnant or breastfeeding individuals
People with known peptide allergies

Overview

Documented preclinical changes include reduced cardiomyocyte apoptosis in aged animal models, improved contractile protein expression, reduced interstitial fibrosis, and partial normalization of oxidative stress markers in myocardial tissue. In limited human clinical data from Russian geriatric studies, treated subjects showed modest improvements in echocardiographic parameters and cardiovascular biomarkers compared to controls.

How it works

Cardiogen acts analogously to a sequence-specific transcription factor mimic: just as a small molecule co-activator may bind to the minor groove of DNA and recruit RNA polymerase II, Cardiogen's dipeptide pairs (Ala-Glu and Asp-Arg) may interact with complementary GC/AT-rich promoter elements in cardiomyocyte-specific gene loci, effectively acting as an exogenous epigenetic modulator rather than a receptor agonist.

After parenteral administration, the tetrapeptide evades rapid enzymatic degradation due to its compact structure and is distributed systemically. Cardiac tissue uptake is hypothesized to occur via passive diffusion and possibly receptor-mediated endocytosis. Within cardiomyocytes, the peptide reaches the nucleus and modulates gene expression profiles, particularly in aged or stressed cells showing epigenetic silencing of cardioprotective loci. Pharmacokinetics remain poorly characterized in peer-reviewed literature; the half-life is expected to be short (<2 hours) given the peptide's size and lack of PEGylation or protective modifications.

Onset & timeline

Molecular effects (gene expression changes) may initiate within hours of administration, but functional physiological changes require cumulative cellular remodeling over 1–4 weeks of repeated dosing, consistent with the bioregulator model of action.

Days 1-3: Peptide distributes systemically; transcriptional modulation begins at the cardiomyocyte nuclear level; no perceptible physiological changes expected
Weeks 1-2: Cumulative gene expression changes lead to upregulation of cardioprotective proteins; early anti-fibrotic and anti-apoptotic effects at the cellular level
Weeks 2-8: Sustained cytoprotective remodeling; potential improvement in myocardial contractile efficiency, reduced oxidative damage markers, and normalization of cardiac biomarkers in compromised subjects; effects likely persist post-cycle due to epigenetic nature of action

Getting the most from it

Monitor resting heart rate and blood pressure at baseline and throughout the cycle
Use bacteriostatic water for reconstitution and maintain strict aseptic technique
Avoid concurrent use of other vasoactive compounds without medical supervision

Common side effects

Injection site reactions (erythema, induration) — most common with IM route
Transient orthostatic hypotension (theoretical, dose-dependent)

Mechanism of action

Cardiogen (Ala-Glu-Asp-Arg) is a tetrapeptide bioregulator functioning via epigenetic mechanisms. Upon cellular internalization, it interacts with chromatin components — specifically histone proteins and promoter regions of cytoprotective genes — modulating transcriptional activity in cardiomyocytes. Evidence from the Khavinson laboratory suggests these short peptides act as transcription factor-like molecules, binding to specific DNA sequences (typically complementary to the encoded amino acid sequence) and upregulating expression of proteins involved in anti-apoptotic signaling (e.g., Bcl-2 family members), extracellular matrix remodeling, and mitochondrial function. This may also involve modulation of NF-κB signaling, reducing pro-inflammatory and pro-fibrotic cascades in aging or ischemic myocardium.

After parenteral administration, the tetrapeptide evades rapid enzymatic degradation due to its compact structure and is distributed systemically. Cardiac tissue uptake is hypothesized to occur via passive diffusion and possibly receptor-mediated endocytosis. Within cardiomyocytes, the peptide reaches the nucleus and modulates gene expression profiles, particularly in aged or stressed cells showing epigenetic silencing of cardioprotective loci. Pharmacokinetics remain poorly characterized in peer-reviewed literature; the half-life is expected to be short (<2 hours) given the peptide's size and lack of PEGylation or protective modifications.

Pharmacodynamics

Molecular effects (gene expression changes) may initiate within hours of administration, but functional physiological changes require cumulative cellular remodeling over 1–4 weeks of repeated dosing, consistent with the bioregulator model of action.

Documented preclinical changes include reduced cardiomyocyte apoptosis in aged animal models, improved contractile protein expression, reduced interstitial fibrosis, and partial normalization of oxidative stress markers in myocardial tissue. In limited human clinical data from Russian geriatric studies, treated subjects showed modest improvements in echocardiographic parameters and cardiovascular biomarkers compared to controls.

Timeline

Days 1-3: Peptide distributes systemically; transcriptional modulation begins at the cardiomyocyte nuclear level; no perceptible physiological changes expected
Weeks 1-2: Cumulative gene expression changes lead to upregulation of cardioprotective proteins; early anti-fibrotic and anti-apoptotic effects at the cellular level
Weeks 2-8: Sustained cytoprotective remodeling; potential improvement in myocardial contractile efficiency, reduced oxidative damage markers, and normalization of cardiac biomarkers in compromised subjects; effects likely persist post-cycle due to epigenetic nature of action

Comparisons

Cardiogen — effectiveness Moderate, safety Good, cost $$, Medium to use
BPC-157 — effectiveness High, safety Good, cost $$, Medium to use
Thymosin Beta-4 (TB-500) — effectiveness High, safety Good, cost $$$, Medium to use

Adverse effects

Common:

Injection site reactions (erythema, induration) — most common with IM route
Transient orthostatic hypotension (theoretical, dose-dependent)

Rare:

Immune-mediated hypersensitivity reactions (rare; incidence not well characterized in literature)
Cardiac rhythm disturbances (theoretical at supratherapeutic doses; not reported in clinical data)

Contraindications & risk mitigation

Contraindicated in:

Patients with decompensated heart failure without cardiologist oversight
Individuals on anticoagulation therapy (due to potential extracellular matrix remodeling effects — theoretical)
Patients with active autoimmune cardiac conditions (myocarditis)

Monitor resting heart rate and blood pressure at baseline and throughout the cycle
Use bacteriostatic water for reconstitution and maintain strict aseptic technique
Avoid concurrent use of other vasoactive compounds without medical supervision

Qué hace

Potential improvements in cardiac-related markers, reduced fatigue linked to poor cardiac output, and general sense of cardiovascular ease — though these are subtle and not universally reported.

Cómo funciona

Imagine your heart cells are like employees who've been working a very long shift — they're tired and making mistakes. Cardiogen is like a manager who walks in, looks at the instruction manual (your DNA), and highlights the right sections so the employees remember how to do their jobs properly again.

After injection, the peptide is absorbed and reaches cardiac tissue, where it interacts with the genetic machinery inside heart muscle cells to encourage healthy protein production and cell maintenance. It does not dramatically stimulate the heart like caffeine or a drug — it works subtly at the cellular level.

Qué esperar

Effects are gradual; most users in research protocols noted changes over 2–4 weeks of consistent use.

Week 1: Body adjusts to the peptide; minimal noticeable changes; injection site reactions may occur
Weeks 2-4: Cellular repair processes begin; some users report slightly improved endurance or reduced chest tightness (anecdotal)
Weeks 4-8: Continued cytoprotective activity; markers of cardiac stress may begin to normalize in research settings; effects plateau and cycle typically ends

Bueno saber

Start with the lower end of the dosing range and assess tolerance
Always use sterile technique for injections to avoid infection

Manteniéndose seguro

Mild soreness or redness at the injection site
Occasional tiredness in the first few days

Evitar si tienes:

Anyone with serious heart conditions who is not under medical supervision
Pregnant or breastfeeding individuals
People with known peptide allergies

Descripción general

Documented preclinical changes include reduced cardiomyocyte apoptosis in aged animal models, improved contractile protein expression, reduced interstitial fibrosis, and partial normalization of oxidative stress markers in myocardial tissue. In limited human clinical data from Russian geriatric studies, treated subjects showed modest improvements in echocardiographic parameters and cardiovascular biomarkers compared to controls.

Cómo funciona

Cardiogen acts analogously to a sequence-specific transcription factor mimic: just as a small molecule co-activator may bind to the minor groove of DNA and recruit RNA polymerase II, Cardiogen's dipeptide pairs (Ala-Glu and Asp-Arg) may interact with complementary GC/AT-rich promoter elements in cardiomyocyte-specific gene loci, effectively acting as an exogenous epigenetic modulator rather than a receptor agonist.

After parenteral administration, the tetrapeptide evades rapid enzymatic degradation due to its compact structure and is distributed systemically. Cardiac tissue uptake is hypothesized to occur via passive diffusion and possibly receptor-mediated endocytosis. Within cardiomyocytes, the peptide reaches the nucleus and modulates gene expression profiles, particularly in aged or stressed cells showing epigenetic silencing of cardioprotective loci. Pharmacokinetics remain poorly characterized in peer-reviewed literature; the half-life is expected to be short (<2 hours) given the peptide's size and lack of PEGylation or protective modifications.

Inicio y cronología

Molecular effects (gene expression changes) may initiate within hours of administration, but functional physiological changes require cumulative cellular remodeling over 1–4 weeks of repeated dosing, consistent with the bioregulator model of action.

Days 1-3: Peptide distributes systemically; transcriptional modulation begins at the cardiomyocyte nuclear level; no perceptible physiological changes expected
Weeks 1-2: Cumulative gene expression changes lead to upregulation of cardioprotective proteins; early anti-fibrotic and anti-apoptotic effects at the cellular level
Weeks 2-8: Sustained cytoprotective remodeling; potential improvement in myocardial contractile efficiency, reduced oxidative damage markers, and normalization of cardiac biomarkers in compromised subjects; effects likely persist post-cycle due to epigenetic nature of action

Cómo aprovecharlo al máximo

Monitor resting heart rate and blood pressure at baseline and throughout the cycle
Use bacteriostatic water for reconstitution and maintain strict aseptic technique
Avoid concurrent use of other vasoactive compounds without medical supervision

Efectos secundarios comunes

Injection site reactions (erythema, induration) — most common with IM route
Transient orthostatic hypotension (theoretical, dose-dependent)

Mecanismo de acción

Cardiogen (Ala-Glu-Asp-Arg) is a tetrapeptide bioregulator functioning via epigenetic mechanisms. Upon cellular internalization, it interacts with chromatin components — specifically histone proteins and promoter regions of cytoprotective genes — modulating transcriptional activity in cardiomyocytes. Evidence from the Khavinson laboratory suggests these short peptides act as transcription factor-like molecules, binding to specific DNA sequences (typically complementary to the encoded amino acid sequence) and upregulating expression of proteins involved in anti-apoptotic signaling (e.g., Bcl-2 family members), extracellular matrix remodeling, and mitochondrial function. This may also involve modulation of NF-κB signaling, reducing pro-inflammatory and pro-fibrotic cascades in aging or ischemic myocardium.

After parenteral administration, the tetrapeptide evades rapid enzymatic degradation due to its compact structure and is distributed systemically. Cardiac tissue uptake is hypothesized to occur via passive diffusion and possibly receptor-mediated endocytosis. Within cardiomyocytes, the peptide reaches the nucleus and modulates gene expression profiles, particularly in aged or stressed cells showing epigenetic silencing of cardioprotective loci. Pharmacokinetics remain poorly characterized in peer-reviewed literature; the half-life is expected to be short (<2 hours) given the peptide's size and lack of PEGylation or protective modifications.

Farmacodinamia

Molecular effects (gene expression changes) may initiate within hours of administration, but functional physiological changes require cumulative cellular remodeling over 1–4 weeks of repeated dosing, consistent with the bioregulator model of action.

Documented preclinical changes include reduced cardiomyocyte apoptosis in aged animal models, improved contractile protein expression, reduced interstitial fibrosis, and partial normalization of oxidative stress markers in myocardial tissue. In limited human clinical data from Russian geriatric studies, treated subjects showed modest improvements in echocardiographic parameters and cardiovascular biomarkers compared to controls.

Cronología

Days 1-3: Peptide distributes systemically; transcriptional modulation begins at the cardiomyocyte nuclear level; no perceptible physiological changes expected
Weeks 1-2: Cumulative gene expression changes lead to upregulation of cardioprotective proteins; early anti-fibrotic and anti-apoptotic effects at the cellular level
Weeks 2-8: Sustained cytoprotective remodeling; potential improvement in myocardial contractile efficiency, reduced oxidative damage markers, and normalization of cardiac biomarkers in compromised subjects; effects likely persist post-cycle due to epigenetic nature of action

Comparaciones

Cardiogen — efectividad Moderate, seguridad Good, costo $$, Medium de usar
BPC-157 — efectividad High, seguridad Good, costo $$, Medium de usar
Thymosin Beta-4 (TB-500) — efectividad High, seguridad Good, costo $$$, Medium de usar

Efectos adversos

Comunes:

Injection site reactions (erythema, induration) — most common with IM route
Transient orthostatic hypotension (theoretical, dose-dependent)

Raros:

Immune-mediated hypersensitivity reactions (rare; incidence not well characterized in literature)
Cardiac rhythm disturbances (theoretical at supratherapeutic doses; not reported in clinical data)

Contraindicaciones y mitigación de riesgos

Contraindicado en:

Patients with decompensated heart failure without cardiologist oversight
Individuals on anticoagulation therapy (due to potential extracellular matrix remodeling effects — theoretical)
Patients with active autoimmune cardiac conditions (myocarditis)

Monitor resting heart rate and blood pressure at baseline and throughout the cycle
Use bacteriostatic water for reconstitution and maintain strict aseptic technique
Avoid concurrent use of other vasoactive compounds without medical supervision

Reference data

Specifications

Molecular formula: C₁₈H₃₀N₆O₉
Molecular weight: 490.47 g/mol
Half-life: ~Unknown; estimated short (<2 hours) based on peptide class
Route: Subcutaneous, Intramuscular
Cycle length: 10–30 days, repeated 2–3 times per year
Storage: Store lyophilized powder at -20°C (freezer). Once reconstituted, refrigerate at 2–8°C and use within 7–10 days. Protect from light and repeated freeze-thaw cycles.
Legal status: Unscheduled research peptide in most Western countries; available as a research compound. Not approved by FDA or EMA for clinical use.

FAQ

Common questions

What is the proposed molecular basis for Cardiogen's cardiac specificity?

The Khavinson group proposes tissue-specific activity of short bioregulatory peptides arises from the complementarity of the peptide's encoded amino acid sequence with specific gene promoter regions active in the target tissue. For Cardiogen, this implies preferential transcriptional activity in cardiomyocyte-specific gene loci, though independent validation of this mechanism in peer-reviewed Western literature remains limited.

How does Cardiogen compare to other cardiac peptides mechanistically?

Unlike BPC-157, which primarily acts through growth factor upregulation (VEGF, EGF) and nitric oxide pathways, or Thymosin Beta-4 which modulates actin polymerization and angiogenesis, Cardiogen's proposed mechanism is epigenetic/transcriptional. This makes it mechanistically distinct and potentially complementary, though direct comparative trials do not exist in the published literature.

Is there clinical-grade evidence for Cardiogen?

Evidence is primarily from Russian-language publications by the Institute of Bioregulation and Gerontology (Khavinson et al.), including some small clinical trials in elderly cardiovascular patients. These have not been replicated in large-scale, double-blind, placebo-controlled Western trials, placing the evidence quality as 'human-limited' by international standards.

What is the evidence level?

This compound is classified as Limited human data. Some human data exists but trials are small, short-term, or not yet replicated.

Research

Research & sources

Limited human

Current evidence for Cardiogen is rated as Limited human data. Limited human data is available.

1. Peptide bioregulation of aging: results and prospects (2010) — Biogerontology 11(2):139-149 — Khavinson VKh, Goncharova ND, Lapin BA
2. Short peptides stimulate the functional activity of cardiomyocytes in vitro (2006) — Bulletin of Experimental Biology and Medicine
3. Tetrapeptide Ala-Glu-Asp-Arg as a geroprotective drug for patients with cardiovascular diseases (2014) — Advances in Gerontology (Uspekhi Gerontologii) — Khavinson VKh et al.

Explore

Often discussed alongside

BPC-157 · healing Epithalon · longevity Selank · cognition Cortagen · cognition